secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001140361-23-038456
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis Q2 revenue $2.1M (-6% YoY); net loss $4.8M; DaVita pilot agreement
---------------------------------------------------------------------------

- Revenue $2.1M, down 6% YoY but up 14% sequentially; gross margin 55.3% (+730 bps).
- Net loss $4.8M ($3.65 per share) vs $4.3M ($40.67 per share) in prior-year period.
- Heart Failure revenue up 8% YoY; Pediatrics down 5% YoY but up 72% sequentially.
- Supply & Collaboration Agreement with DaVita to pilot Aquadex in select U.S. markets.
- Cash $9M, no debt; Mike McCormick appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123038456/0001140361-23-038456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036123038456/brhc20057053_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-038456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer